GT199900147A
(es)
*
|
1998-09-17 |
1999-09-06 |
|
1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
|
US6147089A
(en)
*
|
1998-09-17 |
2000-11-14 |
Pfizer Inc. |
Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
|
US6197786B1
(en)
*
|
1998-09-17 |
2001-03-06 |
Pfizer Inc |
4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
|
US7115279B2
(en)
*
|
2000-08-03 |
2006-10-03 |
Curatolo William J |
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
|
US20060287254A1
(en)
*
|
2001-01-26 |
2006-12-21 |
Schering Corporation |
Use of substituted azetidinone compounds for the treatment of sitosterolemia
|
SE0101161D0
(sv)
|
2001-03-30 |
2001-03-30 |
Astrazeneca Ab |
New compounds
|
AU2002320025A1
(en)
*
|
2001-04-11 |
2002-11-11 |
Atherogenics, Inc. |
Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
|
CN1297541C
(zh)
*
|
2001-04-30 |
2007-01-31 |
辉瑞产品公司 |
制备胆固醇酯转运蛋白抑制剂的方法
|
SK15172003A3
(en)
*
|
2001-06-21 |
2004-11-03 |
Pfizer Prod Inc |
Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
|
EP1404300B1
(en)
|
2001-06-22 |
2009-09-30 |
Pfizer Products Inc. |
Pharmaceutical compositions of dispersions of drugs and neutral polymers
|
EP1269994A3
(en)
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmaceutical compositions comprising drug and concentration-enhancing polymers
|
EP1404302B1
(en)
|
2001-06-22 |
2010-11-03 |
Pfizer Products Inc. |
Pharmaceutical compositions comprising adsorbates of amorphous drug
|
MXPA04005864A
(es)
*
|
2001-12-19 |
2004-10-29 |
Atherogenics Inc |
Derivados de charcona y su uso para tratar enfermedades.
|
US7202247B2
(en)
|
2001-12-19 |
2007-04-10 |
Atherogenics, Inc. |
1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
|
HUP0402309A3
(en)
*
|
2001-12-21 |
2008-09-29 |
Novo Nordisk As |
Amide derivatives as glucokinase activators and pharmaceutical compositions containing them
|
EP1469832B2
(en)
*
|
2002-02-01 |
2016-10-26 |
Bend Research, Inc. |
Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
|
ATE403432T1
(de)
*
|
2002-02-01 |
2008-08-15 |
Pfizer Prod Inc |
Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester- transferproteininhibitors
|
BR0307333A
(pt)
*
|
2002-02-01 |
2004-12-07 |
Pfizer Prod Inc |
Métodos para a preparação de dispersões homogéneas de fármacos sólidos amorfos atomizados utilizando um sistema de secagem por pulverização
|
AR038375A1
(es)
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
EP2471533A1
(en)
*
|
2002-06-27 |
2012-07-04 |
Novo Nordisk A/S |
Aryl carbonyl derivatives as therapeutic agents
|
US20040053842A1
(en)
*
|
2002-07-02 |
2004-03-18 |
Pfizer Inc. |
Methods of treatment with CETP inhibitors and antihypertensive agents
|
US7071210B2
(en)
*
|
2002-07-02 |
2006-07-04 |
Pfizer Inc. |
CETP inhibitors in combination with antihypertensive agents and uses thereof
|
EA011385B1
(ru)
|
2002-10-04 |
2009-02-27 |
Миллениум Фармасьютикалз, Инк. |
Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
|
US7504508B2
(en)
|
2002-10-04 |
2009-03-17 |
Millennium Pharmaceuticals, Inc. |
PGD2 receptor antagonists for the treatment of inflammatory diseases
|
US20090181966A1
(en)
*
|
2002-10-04 |
2009-07-16 |
Millennium Pharmaceuticals, Inc. |
PGD2 receptor antagonists for the treatment of inflammatory diseases
|
CA2500083A1
(en)
*
|
2002-10-21 |
2004-04-29 |
Warner-Lambert Company Llc |
Tetrahydroquinoline derivatives as crth2 antagonists
|
AU2003289207A1
(en)
*
|
2002-12-06 |
2004-06-30 |
Kyowa Hakko Kogyo Co., Ltd. |
Anti-inflammatory agent
|
WO2004056727A2
(en)
*
|
2002-12-19 |
2004-07-08 |
Atherogenics, Inc. |
Process of making chalcone derivatives
|
US20040132771A1
(en)
*
|
2002-12-20 |
2004-07-08 |
Pfizer Inc |
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
|
DE60323536D1
(de)
|
2002-12-20 |
2008-10-23 |
Pfizer Prod Inc |
Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
|
EP1435356A1
(en)
*
|
2003-01-06 |
2004-07-07 |
Warner-Lambert Company LLC |
Quinoline derivatives as CRTH2 antagonists
|
WO2004072042A2
(en)
*
|
2003-02-12 |
2004-08-26 |
Carex S.A. |
Quinoline derivative and their use for modulation of lxr activity
|
US20040225018A1
(en)
|
2003-03-17 |
2004-11-11 |
Japan Tobacco Inc. |
Pharmaceutical compositions of CETP inhibitors
|
CA2519458A1
(en)
*
|
2003-03-17 |
2004-09-30 |
Japan Tobacco Inc. |
Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
|
US20040204450A1
(en)
*
|
2003-03-28 |
2004-10-14 |
Pfizer Inc |
Quinoline and quinoxaline compounds
|
EA200501376A1
(ru)
*
|
2003-03-28 |
2006-04-28 |
Пфайзер Продактс Инк. |
Производные 1,2,4-замещённых 1,2,3,4-тетрагидро- и 1,2-дигидрохинолинов и 1,2,3,4-тетрагидрохиноксалина в качестве ингибиторов сетр для лечения атеросклероза и тучности
|
TWI393560B
(zh)
*
|
2003-05-02 |
2013-04-21 |
Japan Tobacco Inc |
包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合
|
JP4901474B2
(ja)
|
2003-05-30 |
2012-03-21 |
ランバクシー ラボラトリーズ リミテッド |
置換ピロール誘導体
|
WO2005011635A2
(en)
|
2003-08-04 |
2005-02-10 |
Pfizer Products Inc. |
Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
|
CL2004001884A1
(es)
|
2003-08-04 |
2005-06-03 |
Pfizer Prod Inc |
Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
|
WO2005030185A2
(en)
|
2003-09-26 |
2005-04-07 |
Japan Tobacco Inc. |
Method of inhibiting remnant lipoprotein production
|
MXPA06003499A
(es)
*
|
2003-09-30 |
2006-06-08 |
Pfizer Prod Inc |
Inhibidores de proteina de transferencia de esteres de colestrerilo y sus metabolitos.
|
US7749992B2
(en)
*
|
2003-10-08 |
2010-07-06 |
Eli Lilly And Company |
Compounds and methods for treating dislipidemia
|
CA2543596A1
(en)
*
|
2003-11-07 |
2005-05-26 |
Jj Pharma, Inc. |
Hdl-boosting combination therapy complexes
|
CA2551324C
(en)
*
|
2004-01-06 |
2012-11-27 |
Novo Nordisk A/S |
Heteroaryl-ureas and their use as glucokinase activators
|
CA2558766A1
(en)
|
2004-03-05 |
2005-09-22 |
The Trustees Of The University Of Pennsylvania |
The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
|
US7262318B2
(en)
*
|
2004-03-10 |
2007-08-28 |
Pfizer, Inc. |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
WO2005097805A1
(en)
|
2004-03-26 |
2005-10-20 |
Eli Lilly And Company |
Compounds and methods for treating dyslipidemia
|
MY139887A
(en)
|
2004-04-02 |
2009-11-30 |
Mitsubishi Tanabe Pharma Corp |
Tetrahydronaphthyridine derivatives and a process for preparing the same.
|
UA90269C2
(ru)
|
2004-04-02 |
2010-04-26 |
Мицубиси Танабе Фарма Корпорейшн |
Тетрагидрохинолиновые производные и способ их получения
|
WO2006009819A1
(en)
*
|
2004-06-18 |
2006-01-26 |
Array Biopharma Inc. |
Inhibitors of cholesteryl ester transfer protien
|
EP1761521A1
(en)
*
|
2004-06-24 |
2007-03-14 |
Eli Lilly And Company |
Compounds and methods for treating dyslipidemia
|
KR100859223B1
(ko)
*
|
2004-06-24 |
2008-09-18 |
일라이 릴리 앤드 캄파니 |
이상지혈증 치료를 위한 화합물 및 방법
|
US20060063828A1
(en)
*
|
2004-06-28 |
2006-03-23 |
Weingarten M D |
1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
|
US20050288340A1
(en)
*
|
2004-06-29 |
2005-12-29 |
Pfizer Inc |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
DOP2005000123A
(es)
|
2004-07-02 |
2011-07-15 |
Merck Sharp & Dohme |
Inhibidores de cetp
|
ES2539969T3
(es)
*
|
2004-08-25 |
2015-07-07 |
Essentialis, Inc. |
Formulaciones farmacéuticas de activadores del canal de potasio de ATP y usos de las mismas
|
US20070149567A1
(en)
*
|
2004-09-23 |
2007-06-28 |
Pfizer Inc |
Quinoline compounds
|
US20060063803A1
(en)
*
|
2004-09-23 |
2006-03-23 |
Pfizer Inc |
4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
|
ES2328384T3
(es)
*
|
2004-11-23 |
2009-11-12 |
Warner-Lambert Company Llc |
Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
|
WO2006069162A1
(en)
*
|
2004-12-20 |
2006-06-29 |
Reddy Us Therapeutics, Inc. |
Novel heterocyclic compounds and their pharmaceutical compositions
|
ES2644450T3
(es)
|
2004-12-31 |
2017-11-29 |
Dr. Reddy's Laboratories Ltd. |
Nuevos derivados de bencilamina como inhibidores de CETP
|
US8604055B2
(en)
|
2004-12-31 |
2013-12-10 |
Dr. Reddy's Laboratories Ltd. |
Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
|
US8617604B2
(en)
|
2005-02-03 |
2013-12-31 |
Bend Research, Inc. |
Pharmaceutical compositions with enhanced performance
|
KR20070114762A
(ko)
|
2005-02-24 |
2007-12-04 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
염증 질환 치료를 위한 pgd2 수용체 길항제
|
WO2006098394A1
(ja)
*
|
2005-03-14 |
2006-09-21 |
Japan Tobacco Inc. |
脂質吸収抑制方法および脂質吸収抑制剤
|
CN101212966B
(zh)
*
|
2005-07-01 |
2012-03-14 |
默沙东公司 |
合成cetp抑制剂的方法
|
JP2009500377A
(ja)
*
|
2005-07-08 |
2009-01-08 |
ノボ・ノルデイスク・エー/エス |
ジシクロアルキルウレア型グルコキナーゼ活性化剤
|
ATE547396T1
(de)
*
|
2005-07-08 |
2012-03-15 |
Novo Nordisk As |
Dicycloalkylcarbamoyl-harnstoffe als glucokinase- aktivatoren
|
US7884210B2
(en)
*
|
2005-07-14 |
2011-02-08 |
Novo Nordisk A/S |
Ureido-thiazole glucokinase activators
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
JP4681526B2
(ja)
*
|
2005-09-29 |
2011-05-11 |
田辺三菱製薬株式会社 |
医薬組成物
|
JP4531027B2
(ja)
*
|
2005-09-29 |
2010-08-25 |
田辺三菱製薬株式会社 |
医薬組成物
|
RU2008119687A
(ru)
|
2005-10-21 |
2009-11-27 |
Новартис АГ (CH) |
Комбинации органических соединений
|
AU2006313430B2
(en)
|
2005-11-08 |
2012-09-06 |
Ranbaxy Laboratories Limited |
Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
ATE529113T1
(de)
|
2006-01-05 |
2011-11-15 |
Essentialis Inc |
Salze von kalium-atp-kanal-öffnern und ihre verwendungen
|
PE20071025A1
(es)
|
2006-01-31 |
2007-10-17 |
Mitsubishi Tanabe Pharma Corp |
Compuesto amina trisustituido
|
UY30117A1
(es)
|
2006-01-31 |
2007-06-29 |
Tanabe Seiyaku Co |
Compuesto amina trisustituido
|
UY30244A1
(es)
|
2006-03-30 |
2007-11-30 |
Tanabe Seiyaku Co |
Un proceso para preparar derivados de tetrahidroquinolina
|
GB0615670D0
(en)
*
|
2006-08-07 |
2006-09-13 |
Syngenta Participations Ag |
Chemical compounds
|
US7750019B2
(en)
|
2006-08-11 |
2010-07-06 |
Kowa Company, Ltd. |
Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
|
TW200831497A
(en)
*
|
2006-10-12 |
2008-08-01 |
Epix Delaware Inc |
Carboxamide compounds and their use
|
CN101663262B
(zh)
|
2006-12-01 |
2014-03-26 |
百时美施贵宝公司 |
用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
|
JP2010513534A
(ja)
*
|
2006-12-21 |
2010-04-30 |
エージェリオン ファーマシューティカルズ, インコーポレイテッド |
Mtpインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
|
EP2118083A1
(en)
*
|
2007-01-09 |
2009-11-18 |
Novo Nordisk A/S |
Urea glucokinase activators
|
AU2008204530B2
(en)
|
2007-01-11 |
2013-08-01 |
Vtv Therapeutics Llc |
Urea glucokinase activators
|
CN101220021B
(zh)
*
|
2007-01-12 |
2010-12-08 |
上海医药工业研究院 |
4-取代苯氧基喹啉类化合物及其中间体、制备方法和应用
|
US7790737B2
(en)
|
2007-03-13 |
2010-09-07 |
Kowa Company, Ltd. |
Substituted pyrimidine compounds and their utility as CETP inhibitors
|
ES2533910T3
(es)
|
2007-04-13 |
2015-04-15 |
Kowa Company, Ltd. |
Compuesto novedoso de pirimidina que tiene estructura de dibencilamina y medicamento que comprende el compuesto
|
CA2692160A1
(en)
*
|
2007-07-02 |
2009-01-08 |
Essentialis, Inc. |
Salts of potassium atp channel openers and uses thereof
|
MX2010004929A
(es)
|
2007-11-05 |
2010-05-27 |
Novartis Ag |
Derivados de 4-bencil-amino-1-carboxi-acil-piperidina como inhibidores de proteina de transferencia de colesterol-ester (cetp) utiles para el tratamiento de enfermedades tales como hiperlipidemia o arteriosclerosis.
|
ES2425776T3
(es)
|
2007-12-03 |
2013-10-17 |
Novartis Ag |
Derivados 1,2-disustituidos de 4-bencilamino-pirrolidina como inhibidores CETP útiles para el tratamiento de enfermedades tales como hiperlipidemia o arteriosclerosis
|
KR20100102646A
(ko)
|
2007-12-11 |
2010-09-24 |
가부시키가이샤 사이토파스파인더 |
카르복스아미드 화합물 및 케모카인 수용체 길항제로서의 이의 용도
|
BRPI1012852A2
(pt)
|
2009-05-15 |
2018-06-19 |
Novartis Ag |
derivados de benzoxazolona como inibidores da sintase de aldoesterona
|
CN104892502B
(zh)
|
2009-05-15 |
2017-08-04 |
诺华股份有限公司 |
作为醛固酮合酶抑制剂的芳基吡啶
|
KR101442897B1
(ko)
|
2009-05-28 |
2014-09-23 |
노파르티스 아게 |
네프릴리신 억제제로서의 치환된 아미노프로피온산 유도체
|
CN102448928B
(zh)
|
2009-05-28 |
2014-10-01 |
诺华股份有限公司 |
作为中性溶酶(neprilysin)抑制剂的取代的氨基丁酸衍生物
|
AR077208A1
(es)
|
2009-06-30 |
2011-08-10 |
Lilly Co Eli |
Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
|
CN102712589B
(zh)
|
2009-11-17 |
2015-05-13 |
诺华股份有限公司 |
作为醛固酮合酶抑制剂的芳基-吡啶衍生物
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
JP5575913B2
(ja)
|
2009-11-30 |
2014-08-20 |
ノバルティス アーゲー |
アルドステロン合成酵素阻害剤としてのイミダゾール誘導体
|
EP2571860A1
(en)
|
2010-05-21 |
2013-03-27 |
Pfizer Inc |
2-phenyl benzoylamides
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
EP2668507B1
(en)
|
2011-01-26 |
2017-08-23 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Method for assessing a subject's risk of having a cardiovascular disease.
|
US20130345392A1
(en)
|
2011-03-04 |
2013-12-26 |
Pfizer Inc |
Edn3-like peptides and uses thereof
|
MX2013014900A
(es)
|
2011-06-17 |
2014-02-17 |
Merck Sharp & Dohme |
Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de la molecula receptora homologa quimioatrayente expresada en celulas t auxiliares de tipo 2.
|
AR087451A1
(es)
*
|
2011-08-17 |
2014-03-26 |
Lilly Co Eli |
Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
|
CA2845284C
(en)
|
2011-08-18 |
2018-03-06 |
Dr. Reddy's Laboratories Ltd. |
Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors
|
JP6140168B2
(ja)
|
2011-09-27 |
2017-05-31 |
ドクター レディズ ラボラトリーズ リミテッド |
アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質(cetp)インヒビターとしての5−ベンジルアミノメチル−6−アミノピラゾロ[3,4−b]ピリジン誘導体
|
MX347400B
(es)
|
2012-06-29 |
2017-04-18 |
Univ Nac Autónoma De México |
Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
|
UY35144A
(es)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
|
DK2956464T3
(en)
|
2013-02-14 |
2018-07-16 |
Novartis Ag |
Substituted bisphenyl-butane phosphonic acid derivatives as NEP (neutral endopeptidase) inhibitors
|
EP2986599A1
(en)
|
2013-04-17 |
2016-02-24 |
Pfizer Inc. |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
EP3024492A2
(en)
|
2013-07-25 |
2016-06-01 |
Novartis AG |
Bioconjugates of synthetic apelin polypeptides
|
PE20160878A1
(es)
|
2013-07-25 |
2016-09-08 |
Novartis Ag |
Polipeptidos ciclicos para el tratamiento de la insuficiencia cardiaca
|
JP6956005B2
(ja)
*
|
2014-08-28 |
2021-10-27 |
デジマ・ファルマ・ベー・フェー |
コレステリルエステル転送タンパク質阻害剤及びHMG CoA還元酵素阻害剤を含む医薬組成物及び治療併用剤
|
BR112017003745A2
(pt)
|
2014-08-29 |
2017-12-05 |
Tes Pharma S R L |
inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
CU20170093A7
(es)
|
2015-01-23 |
2017-09-06 |
Novartis Ag |
Conjugados de ácidos grasos y apelina sintética con mayor vida media
|
JOP20190086A1
(ar)
|
2016-10-21 |
2019-04-18 |
Novartis Ag |
مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
CN112040945A
(zh)
|
2018-06-12 |
2020-12-04 |
Vtv治疗有限责任公司 |
葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
|
CA3125765A1
(en)
|
2019-01-18 |
2020-07-23 |
Astrazeneca Ab |
Pcsk9 inhibitors and methods of use thereof
|
AR127698A1
(es)
|
2021-11-23 |
2024-02-21 |
Novartis Ag |
Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
|